Skip to main content

Table 4 Baseline clinical profiles and responses after CHP-NY-ESO-1 vaccinations

From: Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients

100 μg 200 μg
pt No. Response to previous therapies (duration time, weeks) *sum of tumor diameters (mm) Tumor response (BOR) Time-to-progression (weeks) Survival (weeks) pt No. Response to previous therapies (duration time, weeks) *sum of tumor diameters (mm) Tumor response (BOR) Time-to-progression (weeks) Survival (weeks)
100-01 PR (4) NA PD 6 31 200-01 PR (29) 24 SD 17 70
100-02 SD 53 NE 4 6 200-02 NE 25 SD 18 33
100-03 NE 144 NE 4 6 200-03 PR (32) 55 PD 6 37
100-04 PD 182 PD 5 17 200-04 PR (30) NA PD 6 50
100-05 CR (38) 101 NE 4 4 200-05 PR (32) NA PD 6 72
100-06 SD 69 PD 6 31 200-06 NE 32 SD 18 54
100-07 CR (15) 78 PD 6 29 200-07 NE 205 NE 6 8
100-08 NE 39 SD 18 23 200-08 PR (12) 16 SD 11 33
100-09 SD 18 PD 6 8 200-09 CR (96) 88 PD 6 45
100-10 CR (24) NA SD 11 60 200-10 SD NA SD 12 48
100-11 SD 31 SD 12 20 200-11 SD NA NE 6 12
100-12 PR (9) NA NE 16 28 200-12 SD NA SD 12 33
100-13 PR (16) NA NE 52 59       
  1. *target lesions determined based on RECIST criteria.